Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
The downside that can come from buying these securities is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. That said, here are three stocks under $10 to swipe left on and some alternatives you should look into instead.
Red Robin (RRGB)
Share Price: $3.33
Known for its bottomless steak fries, Red Robin (NASDAQ: RRGB) is a chain of casual restaurants specializing in burgers and general American fare.
Why Do We Pass on RRGB?
- Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new restaurants
- Falling earnings per share over the last six years has some investors worried as stock prices ultimately follow EPS over the long term
- High net-debt-to-EBITDA ratio of 9× could force the company to raise capital at unfavorable terms if market conditions deteriorate
Red Robin is trading at $3.33 per share, or 8.8x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including RRGB in your portfolio.
Offerpad (OPAD)
Share Price: $0.83
Known for giving homeowners cash offers within 24 hours, Offerpad (NYSE: OPAD) operates a tech-enabled platform specializing in direct home buying and selling solutions.
Why Do We Steer Clear of OPAD?
- Number of homes sold has disappointed over the past two years, indicating weak demand for its offerings
- Projected 10.6 percentage point decline in its free cash flow margin next year reflects the company’s plans to increase its investments to defend its market position
- EBITDA losses may force it to accept punitive lending terms or high-cost debt
Offerpad’s stock price of $0.83 implies a valuation ratio of 0x forward price-to-sales. If you’re considering OPAD for your portfolio, see our FREE research report to learn more.
Novavax (NVAX)
Share Price: $8.65
Pioneering a nanoparticle technology that mimics the molecular structure of disease pathogens, Novavax (NASDAQ: NVAX) develops and commercializes protein-based vaccines for infectious diseases, with a primary focus on its COVID-19 vaccine and combination respiratory vaccine candidates.
Why Are We Hesitant About NVAX?
- Flat sales over the last two years suggest it must find different ways to grow during this cycle
- Projected sales decline of 52% for the next 12 months points to an even tougher demand environment ahead
- Free cash flow margin dropped by 73.8 percentage points over the last five years, implying the company became more capital intensive as competition picked up
At $8.65 per share, Novavax trades at 2.7x forward price-to-sales. Dive into our free research report to see why there are better opportunities than NVAX.
Stocks We Like More
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
